ISSN 1674-3865  CN 21-1569/R
主管:国家卫生健康委员会
主办:中国医师协会
   辽宁省基础医学研究所
   辽宁中医药大学附属医院

中国中西医结合儿科学 ›› 2018, Vol. 10 ›› Issue (5): 409-412.doi: 10.3969/j.issn.1674-3865.2018.05.013

• 实验论著 • 上一篇    下一篇

益气固本胶囊调控哮喘小鼠核因子κB信号通路肿瘤坏死因子α和白细胞介素1β含量的实验研究

孔一卜,孙丽平,刘璐   

  1. 130117 长春,长春中医药大学2017级中医儿科学专业研究生(孔一卜);130021 长春,长春中医药大学附属医院儿童诊疗中心(孙丽平);130117 长春,长春中医药大学2014级中医儿科学专业研究生(刘璐)
  • 出版日期:2018-10-25 发布日期:2018-12-03
  • 通讯作者: 孙丽平,E-mail:slpwzt7063@163.com
  • 作者简介:孔一卜(1991-),男,长春中医药大学2017级博士研究生在读。研究方向:小儿肺系、脾系疾病的中医药防治
  • 基金资助:
    国家自然科学基金面上项目(81473729);吉林省科技发展计划项目(20150101209JC)

Experimental study on the effect of Yiqi Guben capsule in regulating the content of TNF-α、IL-1β in NF-κB signaling pathway of asthma mice

KONG Yibu, SUN Liping,LIU Lu   

  1. Changchun University of Traditional Chinese Medicine,Changchun 130117,China
  • Online:2018-10-25 Published:2018-12-03

摘要:
目的
观察益气固本胶囊对哮喘小鼠血清、肺泡灌洗液中肿瘤坏死因子α(TNFα)、白细胞介素1β(IL1β)含量的影响,探讨益气固本胶囊抑制哮喘气道重塑的作用机制。
方法
将60只BALB/c小鼠随机分为正常对照组(10只)、模型组(14只)、益气固本胶囊组(12只)、地塞米松片组(12只)、童康片组(12只),将益气固本胶囊(55 g/L)、地塞米松片(0.005 g/L)、童康片(44 g/L)给予各药物组灌胃,正常对照组、模型组给予等容积的纯净水灌胃,每日1次,连续30 d。根据文献采用卵蛋白(OVA)致敏建立小鼠哮喘模型。给药后的第21天激发哮喘模型,每日激发1次,连续10 d,激发前1 h药物组给予受试药。用酶联免疫吸附试验(ELISA)法测定给药30 d后小鼠血清和肺泡灌洗液中TNF-α、IL-1β的含量。
结果
模型组小鼠血清中TNFα与正常对照组比较含量升高,差异有统计学意义(P<0.01)。益气固本胶囊组、童康片组、地塞米松组小鼠血清中TNFα与模型组比较含量降低,差异有统计学意义(P<0.05),IL-1β含量无明显差异(P>0.05)。模型组肺泡灌洗液中TNF-α、IL-1β与正常对照组比较含量升高,差异有统计学意义(P<0.01)。益气固本胶囊组、童康片组、地塞米松组小鼠肺泡灌洗液中TNF-α、IL-1β与模型组比较含量降低,差异有统计学意义(P<0.05)。
结论
益气固本胶囊可有效降低哮喘小鼠血清中TNF-α及肺泡灌洗液中TNF-α、IL-1β的含量,推测其可能是通过降低小鼠体内TNF-α、IL-1β的含量抑制NF-κB信号通路的活性从而发挥治疗哮喘的作用。

关键词: 哮喘, 益气固本胶囊, NF-κB, 气道重塑, 小鼠

Abstract:
Objective
To observe the effect of Yiqi Guben capsule on the levels of TNF-α、IL-1β in serum and alveolar lavage fluid of asthmatic mice, and to explore the mechanism of Yiqi Guben capsule in inhibiting airway remodeling in asthma.
Methods
Sixty BALB/c mice were randomly divided into normal control group(n=10),model group(n=14),Yiqi Guben capsules group(n=12),dexamethasone tablets group(n=12) and Tongkang tablets group(n=12).Yiqi Guben capsules(55 g/L),dexamethasone tablets(0.005 g/L)and Tongkang tablets(44 g/L) were given by intragastric administration to each drug group, and normal control group and model group were given equal volume of pure water by intragastric administration, once a day for 30 consecutive days. Asthma mice models were established by sensitization with ovalbumin(OVA) according to the literature. Asthma models were challenged once a day for 10 consecutive days beginning on the 21st day after administration. The drug groups were given the tested drug 1 hour before the provocation. The content of TNF-α and IL-1β in serum and alveolar lavage fluid were determined by enzymelinked immunosorbent assay (ELISA) after 30 days.
Results
Compared with normal control group, Serum levels of TNF-α in model group statistically were significantly  increased(P<0.01). Compare with asthma model group, serum levels of TNF-α in Yiqi Guben capsule group and Tongkang tablet group and dexamethasone tablets group were decreased significantly (P<0.05),serum levels of IL-1β was no statistical significance(P>0.05). Compare with  normal control group,bronchoalveolar lavage fluid levels of TNF-α and IL-1β in model group were significantly  increased(P<0.01).Compare with asthma model group,bronchoalveolar lavage fluid levels of TNF-α and IL-1β in Yiqi Guben capsule group and Tongkang tablet group and dexamethasone tablets  were decreased significantly (P<0.05).
ConclusionYiqi Guben capsule can effectively reduce the levels of TNF-α in serum and TNF-α,IL-1β in bronchoalveolar lavage fluid of asthmatic mice. It is suggested that it may  treat asthma by inhibiting the activity of NF-κB signal  pathway by reducing the levels of TNF-α,IL-1β in mice.

Key words: Asthma, Yiqi Guben capsule, NF-κB, Airway remodeling, Mice